25 results
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Recommendations for Preventing ... Women with in HIV-AIDS ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Infections in HIV-AIDS ... Preventing 1st ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Infections in HIV-AIDS ... • In rare cases ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
CNS Infection in HIV / AIDS - Differential Diagnosis Framework

Principles of HIV-Associated CNS Opportunistic Infections:
 •
/ AIDS - Differential ... complaints or seizures ... Demyelinating disease caused ... aphasia, and/or seizures ... differential #diagnosis #AIDS
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Trypanosomiasis) in HIV-AIDS ... Preventing Clinical ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Encephalitis in HIV-AIDS ... #Treatment #opportunistic ... infections #HIVAIDS #management ... #pharmacology # ... pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis in HIV-AIDS ... Leishmaniasis #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
Recommendations for Preventing ... Disease (MCD) in HIV-AIDS ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... mucosal #IDSA #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
Infections in HIV-AIDS ... #IDSA #Prevention ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology